Aug 10, 2023 / 12:30PM GMT
Operator
Good morning, and welcome to the Galera Therapeutics update conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.
I will now turn the call over to Chris Degnan, Chief Financial Officer of Galera Therapeutics. Thank you, Mr. Degnan. You may begin.
Chris Degnan - Galera Therapeutics, Inc. - CFO
Good morning, everyone. Thank you for joining this conference call, during which we will be discussing the FDA Complete Response Letter received for the new drug application of avasopasem manganese for radiotherapy-induced severe oral mucositis for patients with head and neck cancer. Joining me on this morning's call is Dr. Mel Sorensen, Galera's President and Chief Executive Officer.
Yesterday, we issued a press release announcing that we received a Complete Response Letter from the FDA for avasopasem. And given the impact of the Complete Response Letter, we are taking actions to extend our cash runway. A copy of this press release can be found on our website at galeratx.com. Additionally, a replay of this
Galera Therapeutics Inc To Host Conference Call Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers